Cargando…

Proposing a nasal trehalose‐induced autophagy approach against SARS‐CoV 2

Detalles Bibliográficos
Autores principales:	Pajokh, Mojde, Pourfridoni, Mohammad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474006/ https://www.ncbi.nlm.nih.gov/pubmed/34604543 http://dx.doi.org/10.1002/hsr2.375

Ejemplares similares

Chloroquine drops against SARS-CoV-2 infection
por: Kumar, Jogender, et al.
Publicado: (2022)

Enoxaparin’s potential mechanisms against SARS-CoV-2
por: Afsharirad, Bentelhoda, et al.
Publicado: (2023)

Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics
por: Standl, Fabian, et al.
Publicado: (2021)

COVID‐19 and the increase in schizophrenia incidence in the future: A hypothesis and a serious warning
por: Pourfridoni, Mohammad, et al.
Publicado: (2022)

Fighting the Battle against SARS-CoV-2 as Gastroenterologists in Italy
por: Pagnini, Cristiano, et al.
Publicado: (2020)

Immune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2
por: Chemaitelly, Hiam, et al.
Publicado: (2022)

Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1
por: van Doremalen, Neeltje, et al.
Publicado: (2020)

High-flow nasal oxygen decrease mortality in patients with severe SARS-CoV-2 pneumonia? Issues and controversies
por: Di Costanzo, Domenica, et al.
Publicado: (2022)

Ebselen, a new candidate therapeutic against SARS-CoV-2
por: Haritha, C.V., et al.
Publicado: (2020)

Protection against the Omicron Variant from Previous SARS-CoV-2 Infection
por: Altarawneh, Heba N., et al.
Publicado: (2022)

Non-adjuvanted interferon-armed RBD protein nasal drops protect airway infection from SARS-CoV-2
por: Lin, Yifan, et al.
Publicado: (2022)

Stability of SARS-CoV-2 in different environmental conditions
por: Dehbandi, Reza, et al.
Publicado: (2020)

Sunitinib reduces the infection of SARS-CoV, MERS-CoV and SARS-CoV-2 partially by inhibiting AP2M1 phosphorylation
por: Wang, Pei-Gang, et al.
Publicado: (2020)

Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection
por: Lin, Qingqing, et al.
Publicado: (2020)

Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement
por: Zang, Jinkai, et al.
Publicado: (2020)

Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant
por: Chemaitelly, Hiam, et al.
Publicado: (2021)

Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants
por: Pallett, Scott J C, et al.
Publicado: (2022)

Cross-reactive antibody immunity against SARS-CoV-2 in children and adults
por: Fraley, Elizabeth, et al.
Publicado: (2021)

Heterotypic vaccination responses against SARS-CoV-2 Omicron BA.2
por: Fang, Zhenhao, et al.
Publicado: (2022)

Expression of ACE2—a Key SARS-CoV-2 Entry Factor—Is Not Increased in the Nasal Mucosa of People with Cystic Fibrosis
por: Sala, Marc A., et al.
Publicado: (2022)

Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV
por: Zheng, Ming, et al.
Publicado: (2020)

Pooled saliva samples as an approach to reduce the spread of infections with SARS-CoV-2
por: Möst, Johannes, et al.
Publicado: (2021)

SARS-CoV-2 shedding and infectivity
por: Atkinson, Barry, et al.
Publicado: (2020)

The proximal origin of SARS-CoV-2
por: Andersen, Kristian G., et al.
Publicado: (2020)

SARS-CoV-2 Infection in Children
por: Lu, Xiaoxia, et al.
Publicado: (2020)

SARS-CoV-2 seroprevalence in Spain
por: George, Thukalan Paulose
Publicado: (2020)

SARS CoV2 vaccine and aphasia
por: sookaromdee, Pathum, et al.
Publicado: (2021)

Hybrid SARS-CoV-2 variants
por: Rahimi, Farid, et al.
Publicado: (2022)

SARS-CoV-2 seroprevalence in Spain
por: Hoffmann, Christian, et al.
Publicado: (2020)

Estimates of anti-SARS-CoV-2 antibody seroprevalence in Iran
por: Nazemipour, Maryam, et al.
Publicado: (2021)

SARS-CoV-2 N-gene mutation leading to Xpert Xpress SARS-CoV-2 assay instability
por: Foster, Charles S.P., et al.
Publicado: (2022)

An action plan for pan-European defence against new SARS-CoV-2 variants
por: Priesemann, Viola, et al.
Publicado: (2021)

Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac
por: Chen, Yuxin, et al.
Publicado: (2021)

Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2
por: Takashita, Emi, et al.
Publicado: (2022)

The Uro-oncology Patient and Vaccination Against SARS-CoV-2
por: Rodriguez Socarrás, Moises, et al.
Publicado: (2021)

Re-visiting preoperative SARS-CoV-2 testing using a Bayesian approach
por: Yang, Stephen Su, et al.
Publicado: (2020)

May Parkinson's disease be a protective factor against CNS involvement by SARS-CoV2?
por: Spina Tensini, F., et al.
Publicado: (2020)

Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2
por: Blumenthal, Kimberly G., et al.
Publicado: (2021)

Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC
por: Wall, Emma C, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3p8uipv9msvdabsb45nrk3jrvi